Who are the key vendors in the Global Rheumatoid Arthritis Drugs Market?

Global rheumatoid arthritis drugs market has become moderately competitive. This is partly because there are a number of new drugs available that can help to treat the condition. However, it is also due to the fact that existing drugs are being marketed in a more aggressive way. This means that companies are investing more in marketing their products, which in turn leads to higher sales volumes. The major players in this market are focusing on developing new and innovative products that can address the needs of patients. This is expected to drive the growth of the rheumatoid arthritis drugs market over the forecast period. 'Pfizer Inc.', 'Johnson & Johnson Services, Inc.', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol Myers Squibb Co.', 'Celgene Corporation', 'Eli Lilly and Company', 'F. Hoffmann-La Roche AG', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'Novartis International AG', 'Sanofi S.A.UCB S.A.Biogen Idec Inc.Gilead Sciences, Inc.Astellas Pharma Inc.Daiichi Sankyo Company LimitedEisai Co., Ltd.Ipsen S.A.Kyowa Kirin Co., Ltd.'

What is the key driver of Global Rheumatoid Arthritis Drugs Market?

Rheumatoid arthritis drugs are expensive and patients often end up paying up to USD 30,000 on the medication each year. It has also been found that most of the patients have to cover the expenses out of their pockets and it can be reimbursed by insurance providers, depending on the coverage amount. Despite the insurance coverage, patient has to pay up to 30% of the cost on their own.

What is the key market trend for Global Rheumatoid Arthritis Drugs Market?

Increasing prevalence of rheumatoid arthritis among elderly population. In addition to this, a shift from symptom management to slowing the progression of the disease is driving the growth of the rheumatoid arthritis drugs market.

Which region accounted for the largest share in Global Rheumatoid Arthritis Drugs Market?

North America holds majority share and is likely to maintain its dominant position in the Global Rheumatoid Arthritis Drugs market over the forecast period. Due to the presence of a large population base susceptible to rheumatoid arthritis, increased public awareness about the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in rheumatoid arthritis drug adoption, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, the rise in geriatric population and increased demand for DMARDs contribute to global market growth. Furthermore, the increased focus of top manufacturers on increasing their geographical presence in rising Asia-Pacific countries in order to acquire a large portion of the Global Rheumatoid Arthritis Drugs market is likely to boost growth.

Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2024-2031

Q: What is the global market size of Rheumatoid Arthritis Drugs Market?

Rheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2021 and is poised to grow from USD 60.02 billion in 2022 to USD 70 billion by 2030, growing at a CAGR of 1.72% in the forecast period (2023-2030).

Report ID: SQSG35I2003 | Region: Global | Published Date: October, 2024
Pages: 242 | Tables: 115 | Figures: 69

Rheumatoid Arthritis Drugs Market Competitive Landscape

Competitive Landscape

The global rheumatoid arthritis drugs market is very advanced and rife with competition, with several pharmaceutical firms pushing the boundaries of biologics, DMARDs, and JAK inhibitors. Companies such as AbbVie, Pfizer, Roche, Johnson & Johnson, and Novartis manufactures today’s advanced medicines. These players are more inclined to product portfolio expansion, drug efficiency enhancement, as well as improved health care. Advancements in research and development and the emergence of strategic alliances have allowed these behemoths to have firm control in the sector, which in turn sustains growth and rivalry in the global rheumatoid arthritis drugs market.

Top Player’s in Global Rheumatoid Arthritis Drugs Market

AbbVie, Inc. (US)
Boehringer Ingelheim International GmbH (Germany)
Novartis AG (Switzerland)
Regeneron Pharmaceuticals Inc. (US)
Pfizer Inc. (US)
Bristol Myers Squibb Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
UCB S.A. (Belgium)
Johnson & Johnson Services, Inc. (US)
Amgen, Inc. (US)
Lilly (Eli Lilly and Company) (US)
CELGENE CORPORATION (US)
Gilead Sciences, Inc. (US)
Bausch Health (Canada)
Merck & Co., Inc. (US)
Viatris Inc. (US)
LEO Pharma (Denmark)
Celltrion Inc. (South Korea)
Sun Pharmaceutical Industries Ltd. (India)
Teva Pharmaceuticals Industries Ltd. (Israel)

Rheumatoid Arthritis Drugs Market

Rheumatoid Arthritis Drugs Market Report Snapshots

Rheumatoid Arthritis Drugs Companies

Rheumatoid Arthritis Drugs Market Size

Rheumatoid Arthritis Drugs Market Analysis

Rheumatoid Arthritis Drugs Geographic Analysis

Rheumatoid Arthritis Drugs Market News

License Type

File Type

$5,300
BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION

What is the global market size of Rheumatoid Arthritis Drugs Market?

Rheumatoid Arthritis Drugs Market size was valued at USD 23.61 billion in 2022 and is poised to grow from USD 25.01 billion in 2023 to USD 39.65 billion by 2031, growing at a CAGR of 5.93% in the forecast period (2024-2031).

Who are the key vendors in the Rheumatoid Arthritis Drugs Market?

Competitive Landscape 'AbbVie, Inc. (US) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Novartis AG (Switzerland) ', 'Regeneron Pharmaceuticals Inc. (US) ', 'Pfizer Inc. (US) ', 'Bristol Myers Squibb Company (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'UCB S.A. (Belgium) ', 'Johnson & Johnson Services, Inc. (US) ', 'Amgen, Inc. (US) ', 'Lilly (Eli Lilly and Company) (US) ', 'CELGENE CORPORATION (US) ', 'Gilead Sciences, Inc. (US) ', 'Bausch Health (Canada) ', 'Merck & Co., Inc. (US) ', 'Viatris Inc. (US) ', 'LEO Pharma (Denmark) ', 'Celltrion Inc. (South Korea) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Teva Pharmaceuticals Industries Ltd. (Israel)'

What is the key driver of Rheumatoid Arthritis Drugs Market?

The increasing impact of rheumatoid arthritis around the globe is one of the most important propellers for the expansion of the global rheumatoid arthritis drugs market. As the case of elder population, that it is on the rise, and the eating habits of people are responsible for the incidence of this disease rheumatoid arthritis in addition there is a rising need for effective measures that will help treat this condition which enhances market development.

What is the key market trend for Rheumatoid Arthritis Drugs Market?

Growing Adoption of Biologic Therapies: In the global rheumatoid arthritis drugs industry, medicaments for treatment are developing towards biologics applications which include monoclonal antibodies and JAK inhibitors. Such modern drugs provide targeted action and hence, more desirable results with fewer side effects. The increasing uptake is due to their efficacy in dealing with moderate to severe cases of rheumatoid arthritis.

Which region accounted for the largest share in Rheumatoid Arthritis Drugs Market?

North America is dominating the global rheumatoid arthritis drugs market due to a combination of factors, including high healthcare spending, advanced healthcare infrastructure, and robust research and development activities. The region has a vast clientele base, due to the changing age demographics, increasing rheumatoid arthritis awareness resulting in a greater need for new therapies. Besides, the region is also advanced in therapeutics with access to state-of-the-art biologics, DMARDs, JAK inhibitors alongside an improving drug regulatory regime which fast-tracks drug registration processes. Furthermore, the existence of large pharmaceutical corporations and the rise of individualized medicine are other reasons as to why North America has the highest market share for rheumatoid arthritis therapeutics.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2024-2031

Rheumatoid Arthritis Drugs Market Competitive Landscape

Rheumatoid Arthritis Drugs Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2024-2031

Rheumatoid Arthritis Drugs Market Competitive Landscape

Rheumatoid Arthritis Drugs Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Rheumatoid Arthritis Drugs Market?

Who are the key vendors in the Rheumatoid Arthritis Drugs Market?

What is the key driver of Rheumatoid Arthritis Drugs Market?

What is the key market trend for Rheumatoid Arthritis Drugs Market?

Which region accounted for the largest share in Rheumatoid Arthritis Drugs Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300